DBV TECHNOLOGIES SA-SPON ADR (DBVT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:DBVT • US23306J2006

21.26 USD
-0.2 (-0.93%)
At close: Feb 6, 2026
21.73 USD
+0.47 (+2.21%)
Pre-Market: 2/9/2026, 8:00:03 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall DBVT gets a fundamental rating of 3 out of 10. We evaluated DBVT against 523 industry peers in the Biotechnology industry. While DBVT seems to be doing ok healthwise, there are quite some concerns on its profitability. DBVT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • DBVT had negative earnings in the past year.
  • DBVT had a negative operating cash flow in the past year.
  • In the past 5 years DBVT always reported negative net income.
  • In the past 5 years DBVT always reported negative operating cash flow.
DBVT Yearly Net Income VS EBIT VS OCF VS FCFDBVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • DBVT has a worse Return On Assets (-85.56%) than 70.36% of its industry peers.
  • DBVT's Return On Equity of -142.22% is on the low side compared to the rest of the industry. DBVT is outperformed by 62.72% of its industry peers.
Industry RankSector Rank
ROA -85.56%
ROE -142.22%
ROIC N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
DBVT Yearly ROA, ROE, ROICDBVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • DBVT has a better Gross Margin (91.34%) than 92.93% of its industry peers.
  • DBVT's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for DBVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
DBVT Yearly Profit, Operating, Gross MarginsDBVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • DBVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, DBVT has more shares outstanding
  • DBVT has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, DBVT has a worse debt to assets ratio.
DBVT Yearly Shares OutstandingDBVT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DBVT Yearly Total Debt VS Total AssetsDBVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 7.00 indicates that DBVT is not in any danger for bankruptcy at the moment.
  • DBVT has a Altman-Z score of 7.00. This is in the better half of the industry: DBVT outperforms 76.86% of its industry peers.
  • A Debt/Equity ratio of 0.08 indicates that DBVT is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.08, DBVT is not doing good in the industry: 60.99% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 7
ROIC/WACCN/A
WACC8.17%
DBVT Yearly LT Debt VS Equity VS FCFDBVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 2.45 indicates that DBVT has no problem at all paying its short term obligations.
  • DBVT has a Current ratio of 2.45. This is in the lower half of the industry: DBVT underperforms 70.94% of its industry peers.
  • DBVT has a Quick Ratio of 2.45. This indicates that DBVT is financially healthy and has no problem in meeting its short term obligations.
  • DBVT has a worse Quick ratio (2.45) than 68.64% of its industry peers.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.45
DBVT Yearly Current Assets VS Current LiabilitesDBVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 43.66% over the past year.
  • Looking at the last year, DBVT shows a very strong growth in Revenue. The Revenue has grown by 224.69%.
  • Measured over the past years, DBVT shows a small growth in Revenue. The Revenue has been growing by 0.50% on average per year.
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 16.26% on average over the next years. This is quite good.
  • DBVT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 75.93% yearly.
EPS Next Y-36.93%
EPS Next 2Y-9.86%
EPS Next 3Y24.97%
EPS Next 5Y16.26%
Revenue Next Year-55.09%
Revenue Next 2Y271.45%
Revenue Next 3Y438.04%
Revenue Next 5Y75.93%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DBVT Yearly Revenue VS EstimatesDBVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
DBVT Yearly EPS VS EstimatesDBVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DBVT. In the last year negative earnings were reported.
  • Also next year DBVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBVT Price Earnings VS Forward Price EarningsDBVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBVT Per share dataDBVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as DBVT's earnings are expected to grow with 24.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.86%
EPS Next 3Y24.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DBVT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DBV TECHNOLOGIES SA-SPON ADR

NASDAQ:DBVT (2/6/2026, 8:27:41 PM)

Premarket: 21.73 +0.47 (+2.21%)

21.26

-0.2 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28
Earnings (Next)03-23
Inst Owners69.74%
Inst Owner Change3.82%
Ins Owners0.1%
Ins Owner Change29.3%
Market Cap1.00B
Revenue(TTM)15.73M
Net Income(TTM)-122.55M
Analysts80
Price Target24.48 (15.15%)
Short Float %2.94%
Short Ratio2.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.76%
PT rev (3m)41.94%
EPS NQ rev (1m)23.71%
EPS NQ rev (3m)41.91%
EPS NY rev (1m)11.2%
EPS NY rev (3m)47.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 263.62
P/FCF N/A
P/OCF N/A
P/B 11.63
P/tB 11.63
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)-2.31
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.86
OCFYN/A
SpS0.08
BVpS1.83
TBVpS1.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.56%
ROE -142.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.34%
FCFM N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.61%
Cap/Sales 8.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.45
Altman-Z 7
F-Score2
WACC8.17%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.42%
Cap/Sales(5y)23.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-36.93%
EPS Next 2Y-9.86%
EPS Next 3Y24.97%
EPS Next 5Y16.26%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%N/A
Revenue Next Year-55.09%
Revenue Next 2Y271.45%
Revenue Next 3Y438.04%
Revenue Next 5Y75.93%
EBIT growth 1Y-31.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.76%
EBIT Next 3Y32.47%
EBIT Next 5YN/A
FCF growth 1Y0.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.02%
OCF growth 3YN/A
OCF growth 5YN/A

DBV TECHNOLOGIES SA-SPON ADR / DBVT FAQ

Can you provide the ChartMill fundamental rating for DBV TECHNOLOGIES SA-SPON ADR?

ChartMill assigns a fundamental rating of 3 / 10 to DBVT.


What is the valuation status for DBVT stock?

ChartMill assigns a valuation rating of 1 / 10 to DBV TECHNOLOGIES SA-SPON ADR (DBVT). This can be considered as Overvalued.


Can you provide the profitability details for DBV TECHNOLOGIES SA-SPON ADR?

DBV TECHNOLOGIES SA-SPON ADR (DBVT) has a profitability rating of 1 / 10.